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Clinical characteristics of the study subjects.
Healthy
subjects
Patients with asthma
Steroid-naïve Low-dose
ICS
High-dose
ICS
p value
No. 11 8 13 7
Male/female 7/4 4/4 8/5 1/6 0.177
Age (y) 37 ± 2 57 ± 5 51 ± 4 60 ± 4 <0.001
Allergic, no. 7 4 8 5 0.863Dear Editor,
Asthma is a disease characterized by reversible airﬂow limita-
tion with chronic airway inﬂammation.1 Exhaled breath conden-
sate (EBC) has been reported to be a useful, non-invasive method
for monitoring airway inﬂammation.1 This method can be used to
collect aerosolized particles from airway epithelial lining ﬂuid con-
tained in exhaled breath and can directly measure airway bio-
markers that may contribute to airway inﬂammation. Until now, a
number of mediators had been detected in the EBC from asthmatic
patients, and eicosanoids in EBC have been receiving attention as
biomarkers in asthma.2 Eicosanoids such as cysteinyl leukotrienes
(Cys-LTs), prostaglandins (PGs), and thromboxane (TXs) induce
the airway muscle constriction, airway hyper-responsiveness,
increased vascular permeability, and airway hypersecretion that
are thought to be involved in the airway disease of asthma.3 How-
ever, knowledge about eicosanoids in EBC is still limited. Therefore,
we measured eicosanoids in EBC and analyzed according to the
control status of asthma compared to healthy subjects.
The patients were recruited in Saitama Cardiovascular and Res-
piratory Center. The diagnosis of bronchial asthma was based on
the Japanese Guidelines for Diagnosis and Management of
Asthma.4 The patients divided into two groups according to clinical
control levels of asthma and the dose of inhaled corticosteroids
(ICS) prescribed. Control levels of asthma were deﬁned as previ-
ously described5; in brief, the totally controlled group was deﬁned
by achievement of no symptoms, no exacerbations, no visits to the
emergency room, or no medication-related adverse events. The
cases that did not fulﬁll these criteriawere deﬁned as the not totally
controlled group. Levels of doses of inhaled corticosteroids (ICS)
were deﬁned as low-dose when patients were treated with no
more than 400 mg of ﬂuticasone propionate (FP), or high-dose
when treated with more than 400 mg of FP. The control group con-
sisted of healthy subjects without a history of asthma or any other
allergic disease. EBC samples were collected with a specially
designed condensing chamber (EcoScreen®; Jaeger, Hoechberg,
Germany) in accordance with American Thoracic Society/European
Respiratory Society recommendations.1 The measurements of EBC
were conducted in the Allergy Center of the Saitama Medical Uni-
versity. Concentrations of thromboxane B2 (TXB2), leukotriene B4
(LTB4), prostaglandin D2 (PGD2), and cysteinyl leukotrienes (Cys-
LTs) in EBC were measured using an enzyme-linked immunosor-
bent assay (ELISA) kit with a commercially available system
(Cayman Chemical Company; Ann Arbor, MI, USA). Values arePeer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).expressed as means ± SEM. Two groups were compared using Stu-
dent's t test and more than two groups were compared using a
repeated-measures analysis of variance (ANOVA) with Dunn's mul-
tiple comparison test. Values of p < 0.05 were considered
signiﬁcant.
Twenty-eight patients with asthma were divided into a totally
controlled (n¼ 15) group and a not totally controlled (n¼ 13) group
according to the status of asthma control at the time of sampling.5
Healthy subjects (n ¼ 11) were established, and the groups were
then compared. Additionally, patients with asthma were divided
into an untreated group (naïve, n ¼ 8) and a group treated with
ICS (n¼ 20). The ICS-treated groupwas further divided into a group
treated with low-dose ICS (n ¼ 13) and a group treated with high-
dose ICS (n¼ 7), and theywere once again compared. Table 1 shows
the baseline characteristics for each group. TXB2 could not be
measured in EBC from any of the healthy subjects. In contrast,
TXB2 was detected in 16 of the 28 patients with asthma
(15.7 ± 2.0 pg/mL, 95%CI, 11.5e20.0 pg/mL, Fig. 1A), and was signif-
icantly increased with poorer control subjects (totally controlled vs.
not totally controlled: 12.9 ± 1.8 pg/mL, 95%CI, 8.0e17.8 pg/mL,
n ¼ 5 vs. 17.0 ± 2.7 pg/mL, 95%CI, 11.0e23.0 pg/mL, n ¼ 11,
p < 0.01, Fig. 1B). TXB2 was also increased in the high-dose ICS
group (steroid-naïve vs. low-dose ICS vs. high-dose ICS:
11.5 ± 1.4 pg/mL, 95%CI, 7.5e15.6 pg/mL, n ¼ 5 vs. 15.0 ± 2.8 pg/
mL, 95%CI, 7.7e22.0 pg/mL, n ¼ 6 vs. 20.9 ± 4.6 pg/mL, 95%CI,
8.1e33.7 pg/mL, n ¼ 5, p < 0.01, Fig. 1C). The levels of LTB4 were
increased in untreated patients with asthma (healthy subjects vs.
steroid-naïve asthma: 5.4 ± 0.7 pg/mL, 95%CI, 3.6e7.3 pg/mL,
n ¼ 5 vs. 5.7 ± 0.7 pg/mL, 95%CI, 3.9e7.5 pg/mL, n ¼ 6, p < 0.05),
but not in ICS-treated patients with asthma (data not shown). There
was no signiﬁcant difference regardless of control status (data not
shown). PGD2 were not different between patients with asthma
and healthy subjects (data not shown). Cys-LTs were detectedFEV1
(% predicted)
99.8 ± 2.6 93.0 ± 7.0 81.2 ± 5.9 78.8 ± 10.2 <0.05
ICS, inhaled corticosteroid; FEV1, forced expiratory volume 1.0 s.
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Fig. 1. Concentrations of thromboxane B2 (TXB2) in EBC in healthy subjects and patients with asthma. (A) TXB2 is undetectable in healthy subjects while measurable in 16 patients
with asthma. (B) Patients with asthma were divided into a totally controlled group and a not totally controlled group. (C) Patients with asthma were divided into an untreated group
and an inhaled corticosteroid-treated group, with no more than 400 mg of ﬂuticasone propionate (FP) (low-dose) and a group treated with more than 400 mg of FP (high-dose). Mean
values are shown with horizontal bars. *p < 0.01.
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treated with high-dose ICS (data not shown). The relationship be-
tween eicosanoids in EBC and respiratory function was also exam-
ined, but no signiﬁcant correlation was seen (data not shown).
We conﬁrmed that TXB2 could be measured in EBC obtained
from patients with asthma. TXB2 was increased according to dis-
ease instability, and not affected by ICS. TXB2 is a stable metabolic
product of thromboxane A2 (TXA2). TXA2 is a potent bronchocon-
strictor and also causes airway smooth muscle hyperplasia, a char-
acteristic feature of asthmatic airways, in vitro.6 A metabolic
product of TXB2, 11-dehydro TXB2 (11-DHTXB2), was reported to
be increased during exacerbation of asthma attacks and decreases
when symptoms recede.7 In a study using EBC by Montuschi
et al., problems in the detection rate of TXB2 in patients with
asthma were revealed,8 whereas in a study by Huzar et al., TXB2
was detected in approximately 75% of EBC samples in exercise-
induced asthma cases.9 In the present study, it was demonstrated
that TXB2 in EBC reﬂected asthma instability and was not modiﬁed
by use of ICS. The present study showed the dynamics of TXB2 in
asthmatic airways more thoroughly than previous reports, but
ethnic differences may also need to be taken into account. The use-
fulness of biosynthesis inhibitors and receptor antagonists for TXA2
has been established in asthma treatment in Japan.10 However, the
effect of TXA2 inhibitors in asthma has not really been conﬁrmed in
western countries because no statistically signiﬁcant difference
was observed.11 Therefore, it is possible that TXB2 in EBC might
be a good disease marker of asthma only in a certain ethnic group
such as Japanese population.
In conclusion, while this study only targeted a small number of
Japanese subjects, the present results suggest that TXB2 in EBC may
be a useful indicator for assessing the disease control or severity of
asthma.
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